Answers are grounded in this paper and cite their sources.
Efficient delivery of the Cas endonuclease into target cells avoiding toxic effects remains one of the limiting steps of CRISPR-Cas gene editing technologies. Bacterial conjugation delivers protein and DNA directly into recipient bacteria, since the conjugative relaxase travels through a type IV secretion system covalently attached to the transferred DNA strand. We previously showed that fusion proteins relaxase- Cas12a or relaxase- base editor are translocated by conjugation and recover gRNA-guided nuclease or base-editing activity in recipient bacteria, despite the large size of the fusion. Aiming to improve the efficiency and to broaden the range of susceptible recipient bacteria, here we test translocation of the miniature type V-U4 nuclease Cas12n, fused to two unrelated conjugative relaxases, MobA and TrwC from RSF1010 and R388 respectively. Both fusions of 139 and 168 kDa were stably produced in Escherichia coli donor cells, mobilized their cognate plasmid as efficiently as the wild-type relaxases, and directed guide-dependent cleavage of a chromosomal target in the donor. Translocation and activity in recipient cells were tested with a lethality assay based on the loss of transconjugants viability caused by double-strand breaks introduced by the translocated nuclease. When MobA-Cas12n was delivered together with a mobilizable plasmid which encoded the guide RNA, conjugation frequency was reduced by more than one order of magnitude relative to both a non-targeting guide RNA and a nuclease-free relaxase control, indicating target-specific cleavage of the recipient chromosome. When assayed in parallel with previously characterized TrwC-Cas12a, MobA-Cas12n showed better protein yields and higher activity in recipient cells. This work extends the range of Cas proteins deliverable by conjugative relaxases to miniature nucleases. The fusion with relaxase MobA allows the use of the promiscuous RP4 conjugative system for conjugative delivery, extending the range of recipient bacteria potentially targeted by this tool.
No takes yet. Share an insight, caveat, or question.
Hotten et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: